Education
About Us
Working with TipRanks
Follow Us
Tyra Bioscience (TYRA)
NASDAQ:TYRA
TYRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.40 - $29.60
Previous CloseN/A
Volume80.11K
Average Volume (3M)310.38K
Market Cap
$462.94M
Enterprise Value$485.72M
Total Cash (Recent Filing)$91.97M
Total Debt (Recent Filing)$6.22M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 01, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding53,089,960
10 Day Avg. Volume277,767
30 Day Avg. Volume310,375
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.68
Forecast
1Y Price Target
$29.80Price Target Upside244.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Tyra Bioscience News
PremiumCompany Announcements
Tyra Biosciences Advances Precision Medicine Pipeline
PremiumCompany Announcements
Tyra Biosciences Appoints Adele M. Gulfo to Board---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyTYRA-300 led to an impressive 55% ORR in FGFR3+ mUC patients dosed with >90mg, which is significantly higher than erda's ~35% ORR.
Market PositionTYRA-300 is considered the best-in-class FGFR3 inhibitor.
Regulatory ProgressTYRA-300 Phase 2 trial received IND clearance in NMIBC, viewed as risk-mitigated via mUC data.
Bears Say
Clinical Development RisksRisks include delays in clinical development, negative clinical data, failure to achieve regulatory approval, setbacks with other pipeline assets, and slower-than-anticipated commercial uptake.
Competitive ComparisonThe LY3866288 molecule is less potent and less selective for FGFR3 compared to TYRA-300, with higher toxicity rates.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $8.40 and its highest was $29.60 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $462.94M.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is May 01, 2025 which is in 27 days.
How were Tyra Bioscience’s earnings last quarter?
Tyra Bioscience released its earnings results on Mar 27, 2025. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.474 by $0.044.
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate is -0.49.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 53,089,960 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Tyra Bioscience reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.474. Following the earnings report the stock price went up 1.139%.
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
---
Tyra Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.80 (244.51% Upside)
$29.80 (244.51% Upside)
Hedge Fund Trend
Increased
By 672.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $562.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.45%
12-Months-Change
Fundamentals
Return on Equity
-31.60%
Trailing 12-Months
Asset Growth
61.65%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
---
TYRA Stock 12 Month Forecast
Average Price Target
$29.80
▲(244.51% Upside)
Technical Analysis
Fate Therapeutics
―
Ultragenyx Pharmaceutical
―
Blueprint Medicines
―
Kura Oncology
―
IGM Biosciences
―
Best Analysts Covering TYRA
1 Year
1 Year Success Rate
9/20 ratings generated profit
1 Year Average Return
+6.30%
reiterated a buy rating 4 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 45.00% of your transactions generating a profit, with an average return of +6.30% per trade.
---